

SUBJECT INDEX TO VOLUME 1

<p>Acquired immunodeficiency syndrome (AIDS) 255</p> <p style="padding-left: 20px;">diketoacids in 260</p> <p style="padding-left: 20px;">HIV life cycle in 255</p> <p style="padding-left: 20px;">integrase inhibitors in 259</p> <p style="padding-left: 20px;">integrase protein in 257</p> <p style="padding-left: 20px;">Pol gene in 257</p> <p style="padding-left: 20px;">viral resistance to inhibitors 262</p> <p>Anthraquinone derivatives 116</p> <p>Antibiotic 116,157</p> <p style="padding-left: 20px;">and impact of efflux pumps in bacteria 157</p> <p style="padding-left: 20px;">inhibitors of bacterial efflux pumps as adjuvants in 157</p> <p>Antichlamydial agent 115</p> <p>Anti-drug resistant strain agent 115</p> <p>Anti-fungal compounds 225</p> <p style="padding-left: 20px;">as anti-infective drug target 225</p> <p style="padding-left: 20px;">methods of use 226</p> <p style="padding-left: 20px;">screening tool for 227</p> <p style="padding-left: 20px;">sterol biosynthesis pathway reporter gene to screen for 225</p> <p>Antifungal therapy 75</p> <p style="padding-left: 20px;">for systemic mycoses 75</p> <p>Anti-infective quinone derivatives 113</p> <p style="padding-left: 20px;">antibacterial application of 113</p> <p style="padding-left: 20px;">antifungal application of 121</p> <p style="padding-left: 20px;">antiprotozoal application of 122</p> <p style="padding-left: 20px;">antiviral application of 118</p> <p style="padding-left: 20px;">in HIV 118</p> <p style="padding-left: 20px;">patents of 113</p> <p>Anti-listerial immunity 282</p> <p>Antimicrobial agents 181,189</p> <p style="padding-left: 20px;">as PACT agents featured in patents 191</p> <p style="padding-left: 20px;">clinical application of 189</p> <p style="padding-left: 20px;">effect on viruses 190</p> <p style="padding-left: 20px;">light activated compounds as 181</p> <p>Antimicrobial peptide 201</p> <p>Antimycobacterial 113</p> <p>Antioxidants 17</p> <p style="padding-left: 20px;">effect on cardiovascular health 17</p> <p style="padding-left: 20px;">in cardiovascular dysfunction 23</p> <p style="padding-left: 20px;">in pathological conditions 17</p> <p style="padding-left: 20px;">in sepsis 19</p> <p style="padding-left: 20px;">pharmacological research of 17</p> <p>Antiviral drug 343</p> <p style="padding-left: 20px;">anti-infective applications of 346</p> <p style="padding-left: 20px;">antimicrobial applications of 345</p> <p style="padding-left: 20px;">as anti-inflammatory drugs 346</p> <p style="padding-left: 20px;">as vaccines 346</p> <p style="padding-left: 20px;">based disinfectants 348</p> <p style="padding-left: 20px;">charged dendrimers as 343</p>	<p style="padding-left: 20px;">dendrimers as 344</p> <p style="padding-left: 20px;">receptor binding dendrimers as 344</p> <p>Benzonaphthacenequinone derivative 121</p> <p>BPL1 228</p> <p style="padding-left: 20px;">as antifungal target 228</p> <p>C5a 57</p> <p style="padding-left: 20px;">as therapeutic target in sepsis 57</p> <p>Cancer 242</p> <p style="padding-left: 20px;">use of other small-molecule Raf inhibitors in 243</p> <p style="padding-left: 20px;">use of small-molecule Raf inhibitors in 244</p> <p style="padding-left: 20px;">use of small-molecule urea derivatives in 242</p> <p>CCA1 228</p> <p style="padding-left: 20px;">as antifungal target 228</p> <p>CCR5 275</p> <p style="padding-left: 20px;">as therapeutic targets for HIV infection 275</p> <p style="padding-left: 20px;">role in HIV infection 276</p> <p>CD4 107</p> <p style="padding-left: 20px;">inhibitors of 107</p> <p>Chemokines 147,277</p> <p style="padding-left: 20px;">anti-infective activity of 147</p> <p style="padding-left: 20px;">in diverse interferon agents 153</p> <p style="padding-left: 20px;">in hepatitis C 152</p> <p style="padding-left: 20px;">in non-interferon agents 153</p> <p>Chemokine family 275</p> <p style="padding-left: 20px;">anti-CCR5 antibodies in 278</p> <p style="padding-left: 20px;">nonpeptide small-molecule antagonists in 277</p> <p style="padding-left: 20px;">small peptide antagonists in 277</p> <p style="padding-left: 20px;">TAK-779 in 277</p> <p>Chemokine receptor inhibitors 107</p> <p>Chemokine/chemokine receptor system 277</p> <p style="padding-left: 20px;">inhibitors targeting interaction of 277</p> <p>Chronic hepatitis B 85</p> <p style="padding-left: 20px;">HBeAg-positive 87</p> <p style="padding-left: 20px;">host/HBV genetic polymorphisms in 92</p> <p style="padding-left: 20px;">peginterferon alfa-2a in 87</p> <p style="padding-left: 20px;">peginterferon alfa-2b in 87</p> <p style="padding-left: 20px;">pegylated interferons for 85</p> <p style="padding-left: 20px;">role of peginterferons in management of 90</p> <p style="padding-left: 20px;">treatment of 85</p> <p>Cold virus fusion 247</p> <p>Cysteine protease inhibitors 121</p> <p>Cytokines 147</p> <p style="padding-left: 20px;">anti-infective activity of 147</p> <p style="padding-left: 20px;">as immunomodulators 147</p> <p style="padding-left: 20px;">in diverse interferon agents 153</p>
---	---

in hepatitis C	152	nucleic acid-based therapy for	50
in non-interferon agents	153	nucleoside analogs for	50
Dendrimer	333	protease/helicase inhibitors for	50
antibacterial applications of	341	proteins of	45
antiviral applications of	342	reproductive cycle of	45
based anti-infective	333	viral entry inhibitors for	51
based anti-inflammatory drugs	333	Flavivirus antiviral drug discovery	45
biological considerations of	335	Free radicals	17
cationic antibacterial based	341	in sepsis	19
design of	335	HBeAg-negative chronic hepatitis B	90
history/design of	333	peginterferon alfa-2a in	90
mechanisms for anti-microbial activity of	337	Heart failure	24
receptor-binding antibacterial based	342	role of oxidative stress in	24
Drug virotherapy	317	Hepatitis B	152
Efflux pumps	160	Hepatitis C virus (HCV)	323
biological inhibition of	160	acyclic nucleosides for	325
pharmacological inhibition of	160	2'-fluoronucleosides for	325
Efflux pumps inhibitor	168	2'-modified nucleosides for	324
alkoxyquinolines as	169	3'-modified nucleosides for	325
alkylaminoquinolines as	169	4'-modified nucleosides for	325
aminoglycoside analogs as	169	nucleoside/nucleotide inhibitors for	323
analysis of	168	Heterocyclic quinones	120
aromatic amides as	169	as pharmaceutical agents	120
fluoroquinolone analogs as	169	HIV	148,275
indoles as	169	colony-stimulating factors in	154
peptidomimetics as	170	cytokine inhibitors in	154
piperidine-carboxylic acid derivatives as	169	interferons in	152
tetracycline analogs as	168	RANTES/MIP ligands in	150
thioalkoxyquinolines as	169	targeting CCR5/CXCR4 in	150
ureas as	169	HIV entry inhibitors	67
Enfuvirtide	67	HIV-1	277
clinical trials of	67	inhibitors targeting interaction of	277
molecular-level action of	69	HIV-1 entry	107
Enzymes	101	inhibition of	107
in cellular metabolism	101	into cells	107
in virulence/persistence	102	HIV-1 integrase (HIV-1 IN)	1
Experimental sepsis	59	antiviral activity of	6
anti-C5A treatment reduces multi-organ		catalytic roles of	3
failure (MOF) in	59	inhibitors of integration of	6
Flavivirus	45	preincubation by	5
antiviral compounds for	51	structure of	1
chimeric flavivirus vaccines for	48	HIV-1 integrase inhibitor	1
flavivirus antivirals for	49	benzopyruvic acid derivatives as	6
flavivirus DNA vaccines for	48	classes of	6
flavivirus RNA vaccines for	49	clinical trials as	10
flavivirus subunit vaccines for	49	8-hydroxyquinoline derivatives as	9
genome structure of	45	natural products as	10
heterologous virus vaccines for	48	patent of	1
inhibitors of assembly of	51	polyphenols as	10
inhibitors of nucleoside triphosphate		secondary pharmacophore of	6
synthesis for	51		
intravenous immunoglobulin based therapy for ...	50		

Proteases	209	glycyrrhizin as	305
as anti-infective agents	209	membrane fusion inhibitors as	300
patents on	209	niclosamide as	304
Protease inhibitor	210	valinomycin as	305
aspartic protease inhibitors as	212	viral entry inhibitors as	297
kinase inhibitors as	216	SARS-COV helicase	303
Raf kinase inhibitors as	219	as drug target	303
serine protease inhibitors as	215	SARS-COV polymerase	302
tyrosine kinase inhibitors as	216	as drug target	302
Proteins	96	effect of ribavirin	302
in cell envelope metabolism	96	SARS-COV proteases	300
in transcription/translation	99	as drug target	300
of signal transduction pathways	100	SEC14	228
Psoralens	191	as antifungal target	228
Psoriasis	353	Sepsis	18,57
adhesion molecule targets of	360	antioxidant protection in	26
angiogenesis targets of	360	blockade of C5A/C5AR improves survival in	57
biologicals for	354	lipopolysaccharide (LPS) signaling in	19
chemokine targets of	360	nitrogen species in	22
cytokine antagonism in	356	signaling pathways in	18
etanercept in	358	Severe acute respiratory syndrome (SARS)	297
IFN/IFN antagonism in	358	effect of interferons/interferon inducers	304
IL-2/IL-12 p40 antagonism in	358	Small molecule inhibitors	249
immunopathogenesis of	354	Stopping fusion cold	247
innate immunity targets of	359	Systemic inflammatory response syndrome (SIRS)	57
TNF- α receptor antagonism in	358	anti-C5A treatment for	58
treatment of	353	blockade of C5A improves neutrophil	
Pyrroline-5-carboxylate reductase	226	function in	60
methods for identification of inhibitions of	226	patents on C5AR blocking for	62
methods of using glucan synthase pathway			
reporter genes to screen for	227		
Raf	241	T-1249	69
development of small-molecule inhibitors of	241	molecular-level action of	69
regulation of	241	Tetrahydroxybenzene	231
RAS/RAF/MEK/ERK pathway	241	1,2,3,4-	
inhibition of	241	antimicrobial activity of	236
Recombinant poxviruses	310,314	antioxidant activity of	236
as oncolytic viruses	314	bioengineered synthesis of	238
expression of modulating agents by	317	chemical synthesis of	237
expression of tumor-associated antigens/		method of using	236
immunomodulatory agents by	310	testing antimicrobial activity of	236
Rifamycins	36	TRL1	229
mechanism of action of	36	as antifungal target	229
Rifapentine	37	Tuberculosis	33,95,113
SARS coronavirus (SARS-CoV)	297	anti-TB drugs for	36
anti-infectives for	297	attack on scourge of	95
effect of interferons/interferon inducers	304	drugs against	33
SARS-COV anti-infectives	297	fluoroquinolones in	39
cathepsin L inhibitors as	300	linezolid in	40
chloroquine as	300	moxifloxacin in	39
classes of	297	naphthoquinone derivatives in	113
		PA-824 in	42
		patented drug targets for	95
		rifabutin in	38
		rifalazil in	38

rifametane in	39	Viral attachment	107
rifamycins in	36	inhibitors of	107
rifapentine in	37	Viruse	291
treatment for	33	chemical inactivation of	291
Vaccines	45,282	physical inactivation of	293
development of	45		